Sandoz Group AG (SDZNY)
Market Cap | 18.52B |
Revenue (ttm) | 10.38B |
Net Income (ttm) | n/a |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | 0.53 (1.23%) |
Ex-Dividend Date | Apr 22, 2025 |
Volume | 6,157 |
Average Volume | 37,893 |
Open | 42.11 |
Previous Close | 42.21 |
Day's Range | 42.11 - 43.12 |
52-Week Range | 27.79 - 49.81 |
Beta | n/a |
RSI | 46.91 |
Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Sandoz: Upgrading To A Buy On 2028 Expectations

Sandoz signs landmark supply and manufacturing agreement
BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...
Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE
BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
Sandoz Group AG Non-GAAP EPS of $2.71, revenue of $10.36B; initiates FY25 outlook

Sandoz reports strong FY 2024 results and Q4 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2....

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upf...

Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil...

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications

MS patients suffer side-effects after NHS England switches to cheaper drug
Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money ‘It was awful for me’: one MS patient shares her experience with Tyruko Scores of peopl...

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars...

Francisco Ballester to retire; Peter Stenico appointed President Region International
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, cu...

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Eur...
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz
Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

Intra-Cellular settles Caplyta patent dispute with Sandoz
Intra-Cellular Therapies (ITCI) stock jumps as the company settles a patent dispute with Sandoz (SDZNY) over Caplyta. Read more here.
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation
Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation

Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion
Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.

Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.

Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S.
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking a significant additio...

Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivale...

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the A...